What You Should Know:
- Verily, Alphabet's precision health subsidiary, today announced Lightpath, a next-generation chronic care solution designed to address the evolving needs of health plans and their members.
- The initial offering, Lightpath Metabolic, focuses on empowering individuals with cardiometabolic conditions to achieve and maintain their health goals. Open enrollment is targeted for early 2026.
Building on Success with Onduo
Lightpath Metabolic leverages the
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Blood Test for Alzheimer’s on the Horizon: ALZpath Licenses pTau217 Antibody to Roche
What You Should Know:
- ALZpath, a leader in Alzheimer's disease diagnostics, announced a licensing agreement with Roche for their innovative pTau217 antibody. This paves the way for a blood test to diagnose Alzheimer's disease using Roche's widely used Elecsys® platform.
- The Roche pTau217 test has already received Breakthrough Device designation from the FDA and will be commercialized as part of a collaboration between Roche and Eli Lilly.
pTau217: A Game Changer in
Read More
Helix Launches Clinico-Genomic Datasets to Accelerate Precision Medicine Drug Discovery
What You Should Know:
- Helix, a leader in population genomics, is launching new datasets designed to empower life science companies in developing precision medicine therapies.
- These comprehensive datasets, built through collaborations with various health systems, provide researchers with a rich resource for drug discovery and development across multiple disease areas.
Unveiling the Power of Clinico-Genomic Data
The datasets offer a unique combination of longitudinal
Read More
Nucleus RadioPharma Secures Investment from AstraZeneca
What You Should Know:
- Nucleus RadioPharma, the world's first comprehensive radiopharmaceutical organization, today announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
- The strategic investment bolsters Nucleus' mission to make targeted radiotherapies and theranostics more accessible to patients worldwide.
AstraZeneca Joins Forces with Leading Radiopharmaceutical Innovator
AstraZeneca joins a distinguished group of
Read More
OncoHost and Dana-Farber Partner on Kidney Cancer (RCC) Biomarker Study
What You Should Know:
- OncoHost, a company pioneering personalized medicine approaches for better patient outcomes, announced a collaborative research study with Dana-Farber Cancer Institute, a leading cancer treatment and research center.
- The project aims to identify biomarkers in blood for renal cell carcinoma (RCC), a type of kidney cancer.
The Challenge of Personalized Treatment for RCC:
While immune-checkpoint inhibitor (ICI) therapy has revolutionized RCC treatment,
Read More
IRT: The Unsung Hero of Modern Clinical Trials
The modern landscape of clinical trials is expanding to include hybrid and decentralized approaches to conducting research. As the methods of conducting clinical trials diversify, clinical trial logistics also increase in complexity. In 2024, experts estimate that 50% of clinical trials will be conducted via hybrid or decentralized methods. Though increasing remote access in clinical trials improves convenience, reduces costs and expands diversity, it also presents new challenges in navigating
Read More
Securing the Drug Supply Chain: How Simulation Tech is Aiding Electronic Drug Tracing in the US
The United States drug supply chain is a complex and decentralized system that involves multiple entities. This includes suppliers, distributors, manufacturers, repackagers, wholesale distributors, third-party logistics providers (3PLs), dispensers, and medical facilities such as hospitals and retail stores. To protect this system against potential threats and the illegal movement of counterfeit drugs, the Drug Supply Chain Security Act (DSCSA) was enacted in 2013.
With more than a decade of
Read More
Weave Bio Launches for AI-Powered Drug Development, Secures $10M
What You Should Know:
- Weave Bio, an AI-native life sciences platform company, announced today the public release of its flagship offering, AutoIND, and $10 million in seed funding co-led by Innovation Endeavors and Magnetic Ventures.
- AutoIND marks a significant advancement in drug development by automating and accelerating the preparation, writing, and review process for Investigational New Drug (IND) applications.
Automating the IND Process: A Game-Changer for Drug
Read More
Medable Partners with Masimo to Bring Wearable Devices to Clinical Research, Capturing Better Data
What You Should Know:
- Medable Inc., a leader in modern clinical trial technology, has announced a groundbreaking partnership with Masimo (NASDAQ: MASI) to integrate medical-grade wearable devices into clinical research. This collaboration aims to streamline patient participation and enhance data collection for clinical trials.
- By offering a patient-centric approach and fostering richer data collection, this collaboration holds promise for faster drug development, improved patient
Read More
Sanofi, Formation Bio, OpenAI Partner on AI-Powered Drug Discovery
What You Should Know:
- Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.
- Sanofi, Formation Bio, and OpenAI believe this collaboration will be
Read More
